If you have metastatic castration-resistant prostate cancer (mCRPC) and your oncologist has mentioned Lu-177 PSMA therapy as a next step, an important early question is what it will cost. This article is for patients on the PSMA track - men with advanced prostate cancer exploring lutetium Lu 177 vipivotide tetraxetan, sold as Pluvicto in the US and UK. It compares out-of-pocket costs across three countries: India, the United States, and the UK private sector. The gap is wide enough that knowing the numbers before you call a hospital can change your decision.
How Does Lu-177 PSMA Cost Compare in India, the US, and the UK?
| Factor | India - Private Centre | US - Pluvicto (2026) | UK Private (2022 est.) |
|---|---|---|---|
| Drug cost per cycle | INR ~125,000 at one studied Indian centre (2024 peer-reviewed data); international-patient rates at private hospitals vary - request a written quote | USD ~51,168 wholesale acquisition cost (January 2026) | GBP ~12,000 per cycle (community-reported 2022 estimate; confirm with provider before travel) |
| Full course - up to 6 cycles, drug only | INR ~750,000+ based on per-cycle published figure; international pricing varies by hospital | USD ~307,000+ in drug costs alone (6 x WAC, before admin and imaging) | GBP ~72,000+ (6 x 2022 estimate; unconfirmed at current rates) |
| PSMA-PET eligibility scan | Varies by centre - request a written quote from the hospital in advance | Varies by centre - often not included in the treatment quote | GBP ~2,500 (community-reported 2022 estimate; confirm with provider) |
| Government or insurance coverage | No coverage for international patients; some domestic subsidies for Indian nationals at government centres | Medicare covers Pluvicto for eligible beneficiaries; commercial insurance varies widely | NHS Cancer Drugs Fund access for UK residents only; private insurance rarely covers |
| Access for international patients | Open - major private centres routinely treat patients from the GCC, Africa, and South Asia | Open if visa obtained; full list-price cost applies without insurance | Private hospitals accessible; NHS treatment restricted to UK residents |
Sources: US wholesale acquisition cost from the official Pluvicto cost page (January 2026). India per-cycle figure from a 2024 peer-reviewed study on Lu-177 PSMA-617 in India, published on PubMed Central. UK figures are community-reported estimates from 2022 and should be verified directly with the treating centre. All figures are starting points, not confirmed prices.
The key finding is clear. The drug cost alone in the US is roughly four times the published per-cycle cost at one major Indian institution. For patients without comprehensive US insurance, that difference is large enough that travelling to India often costs less overall, even after adding flights and accommodation. UK private patients pay considerably less per cycle than the US list price, but a full course still costs significantly before scan and hospital fees are counted.
Why Is There Such a Large Price Gap?
Three things drive the difference: drug manufacturing arrangements, hospital overhead, and how each country's government shapes pricing.
In the United States, Pluvicto comes through an FDA-approved commercial chain. The manufacturer sets the wholesale acquisition cost. Most patients with Medicare coverage pay less than the list price, while international visitors without US insurance pay the full bill. The FDA has expanded its approval of lutetium Lu 177 vipivotide tetraxetan to earlier stages of mCRPC, which broadens access for insured US patients, but keeps the list price the same for uninsured patients.
In India, several academic and private centres produce or procure the radiolabelled compound through different supply arrangements. A 2024 peer-reviewed study found that the cost of 100 millicuries of labelled Lu-177 PSMA-617 was approximately INR 80,000 at one Indian centre, with the total per-cycle cost including investigations and admission totaling around INR 125,000. Lower hospital operating costs and high patient volumes at specialist nuclear medicine departments help keep per-cycle prices well below those in the US or UK.
In the United Kingdom, NHS England has approved Lu-177 PSMA therapy through the Cancer Drugs Fund for eligible patients. However, NHS-funded treatment is available only to UK residents who meet specific clinical criteria. International patients must use private UK hospitals, where private hospitals don't publish pricing. The Prostate Cancer Foundation has noted that access constraints for this therapy extend globally - not just in cost, but in the availability of trained nuclear medicine teams and radiopharmacy infrastructure - and this limits where treatment can actually be received.
What Is the Real Cost When You Add Everything Up?
The drug cost is only one part. When planning a full course - up to six cycles spaced six weeks apart, as in the phase 3 VISION trial that supported FDA approval - you need to account for several other items:
- PSMA-PET eligibility scan: This confirms your tumors express PSMA protein at sufficient levels for the therapy to reach them. Some centres include the scan in a bundled price; many charge it separately.
- Blood tests and kidney monitoring: You get blood tests and kidney monitoring to check kidney and bone marrow function before each cycle. The treating centre may include these costs or charge them separately if done at home before you travel.
- Hospital day-procedure or admission fee: Even as an outpatient treatment, room fees and nursing time add cost. At Indian private hospitals serving international patients, they typically bundle this into the per-cycle quote.
- Travel, accommodation, and visa costs: For patients flying to India, plan for two to three weeks per visit if you receive one or two cycles per trip. Some patients choose to stay in India between cycles to reduce total travel costs.
- Response imaging after cycles two or three: Your doctor typically orders a follow-up PSMA-PET or CT scan mid-course to assess whether the therapy is working. You may need to pay for this separately unless your treatment package includes it.
Whether it makes financial sense to stay in India between cycles or fly home after each one depends on your personal circumstances. The article on whether Lu-177 PSMA therapy in India is worth the travel cost covers this calculation in more detail, including estimates for accommodation and return airfares from common source markets.
Does Insurance Help International Patients?
Most standard international health insurance policies don't cover planned medical travel for cancer treatment abroad. However, some policies do - particularly global health policies held by expatriates or GCC nationals with comprehensive coverage. Before assuming your policy won't cover it, check for three things:
- Whether radiopharmaceutical therapy or radioligand therapy is specifically covered (some plans cover chemotherapy but exclude nuclear medicine treatments by category)
- Whether treatment requires pre-authorisation before the first cycle
- Whether the insurer has an established direct-billing arrangement with the hospital you plan to use
For US patients, you can access Medicare coverage for Pluvicto in approved settings if you are an eligible beneficiary, which significantly reduces out-of-pocket costs. The ASCO Daily News has noted that financial and logistical barriers still exist within the US, and cost is a real problem for many mCRPC patients without adequate coverage. US patients without insurance sometimes look into India as an alternative because the uninsured US cost is out of reach.
Is India a Realistic Choice for International Patients?
Yes, for many patients it is. Large nuclear medicine programmes in cities such as Mumbai, Delhi, Hyderabad, Chennai, and Bengaluru have experience treating patients from the Gulf states, East Africa, Bangladesh, Sri Lanka, Nepal, and Myanmar. These centres routinely handle medical records in English, coordinate PSMA-PET scans on arrival, and manage the radiation safety steps that affect travel after each treatment cycle.
The most important step before booking any flights is confirming eligibility. You need a PSMA-PET scan showing high expression of PSMA protein across your tumour deposits. If you haven't had this scan yet, you can usually arrange it in India as part of your arrival workup. If you already have a recent scan from your home country, you can arrange a remote review before you travel. You can request a Lu-177 eligibility review through Art of Healing Cancer, including a remote read of your PSMA-PET images, before committing to any flights - and if Lu-177 PSMA doesn't fit your case, the team can also discuss what alternatives may be worth exploring with your oncologist.
The article on getting a Lu-177 PSMA second opinion before your India flight explains what documents and scans to include in that review, and what questions to ask before committing to treatment abroad.
If Lu-177 PSMA Is Not Available at Home
Many countries - including most of the GCC, much of sub-Saharan Africa, and parts of South and Southeast Asia - don't yet have active Lu-177 PSMA programmes. Patients in those regions either access the therapy abroad or continue on whatever standard treatments are available locally.
If you are at this decision point and unsure whether this therapy is right for you, the most useful first step is a teleconsult with a nuclear medicine team that regularly treats international patients. They can review your scan, your treatment history, and your recent blood results, and give you an honest read on whether you are likely to be a strong candidate. If you are not, they can also point you toward what other options may be appropriate.
For more on pricing at Indian centres - including what a typical international-patient package includes and how to request an itemised written quote - the article on Lu-177 PSMA therapy cost in India for international patients goes into more detail.
A Note on Price Changes Over Time
Radiopharmaceutical pricing shifts from year to year. The US list price for Pluvicto has changed since the drug's first FDA approval in 2022. Indian hospitals set their own rates for international patients. Most private UK hospitals don't publish prices.
The figures in this article reflect the best available published data at the time of writing (2025-2026). Use them as a starting framework for your research, not as a confirmed price. Always request a written, itemised quote from the treating centre before booking travel or signing any agreement.
When to Talk to Your Doctor
Talk to your oncologist or urologist before making any plans to travel for Lu-177 PSMA therapy. Bring your most recent PSMA-PET report, your PSA trend over the past six to twelve months, and a full list of treatments you have already received. Ask your doctor to write a brief treatment summary in English - most Indian nuclear medicine centres will request this before the first consultation. If your home doctor hasn't worked with radioligand therapy, a second opinion from a nuclear medicine specialist is a reasonable step before planning any trip abroad.
If you want to send your scans and medical history for a remote eligibility review before committing to any centre, you can reach the Lutetium Therapy team through the contact form here. If Lu-177 PSMA doesn't fit your case, the team can also discuss what alternatives may be worth exploring with your oncologist.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
How much does one cycle of Lu-177 PSMA therapy cost in India for international patients?
A 2024 peer-reviewed study published on PubMed Central found the drug and facility cost at one Indian centre to be approximately INR 125,000 per cycle. At major private hospitals serving international patients, prices may be higher. Request a written, itemised quote from the hospital before travelling, as pricing varies by facility and patient complexity.
Does Medicare cover Pluvicto in the US?
Yes, Medicare covers Pluvicto for eligible beneficiaries in approved treatment settings. Your out-of-pocket cost depends on your specific Medicare plan and any supplement coverage you hold. Without Medicare or adequate commercial insurance, US patients face the full wholesale acquisition cost, which was approximately USD 51,168 per cycle as of January 2026.
Can international patients get Lu-177 PSMA therapy on the NHS in the UK?
No. The NHS Cancer Drugs Fund approval for Lu-177 PSMA therapy in England applies only to UK residents who meet specific clinical criteria. International visitors must use private UK hospitals and pay out of pocket. Contact the nuclear medicine department at a private UK hospital for current pricing, as tariffs are not widely published.
What is the total drug cost for a full course of Lu-177 PSMA therapy in the US without insurance?
Based on the wholesale acquisition cost of approximately USD 51,168 per cycle as of January 2026, a course of six cycles involves roughly USD 307,000 in drug costs alone, before hospital admission, administration, imaging, and nursing fees. Actual out-of-pocket cost varies significantly based on insurance coverage.
Why is Lu-177 PSMA therapy less expensive in India than in the US or UK?
India benefits from lower hospital operating costs, a well-developed nuclear medicine infrastructure, and in some centres, access to indigenously produced radiolabelled compounds. These factors combine to produce significantly lower per-cycle costs than in countries where the drug moves through a commercial pharmaceutical supply chain at manufacturer-set list prices.
What documents do I need when travelling to India for Lu-177 PSMA therapy?
You will typically need a recent PSMA-PET scan report and images (on CD or via a secure cloud link), your PSA history over at least the past six to twelve months, a summary of all previous treatments, your most recent blood results including kidney function, and a referral letter or treatment summary from your oncologist. Most Indian private centres request these before the first consultation.
